secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001127537-21-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q3 revenue $13.3M (+25% YoY); net loss $10.2M; maintains FY guidance $49-51M
--------------------------------------------------------------------------------

- Worldwide revenue $13.3M, up 25% YoY ($10.6M Q3 2020); U.S. revenue $6.9M (+28%), international $6.4M (+22%).
- Gross margin improved to 73% (70% prior year); net loss $10.2M ($0.28 loss per share) vs $3.9M ($1.37 loss per share).
- Added 18 new U.S. Zephyr Valve treating centers (total 198); positive coverage decisions from Anthem, BCBS Michigan, Horizon NJ (~44M covered lives).
- Cash, cash equivalents, and marketable securities totaled $202.6M as of September 30, 2021.
- Maintains FY 2021 revenue guidance $49-51M; expects near low end due to COVID headwinds; operating expenses guided $83-85M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753721000045/0001127537-21-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753721000045/lung-20211102.htm
  HTML page:      https://secwatch.observer/filing/0001127537-21-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer